Amarantus to Present at the Neurotech Investing and Partnering Conference on Tuesday, April 7, 2015
March 23 2015 - 8:05AM
Amarantus BioSciences Holdings, Inc. (OTCQB:AMBS), a biotechnology
company focused on developing diagnostics in neurology, and
therapeutic products with the potential for orphan drug designation
in the areas of neurology, psychiatry, ophthalmology and
regenerative medicine, announced that Gerald E. Commissiong,
President & CEO, will be presenting at the Neurotech Investing
and Partnering Conference being held April 7-8, 2015 at the Hotel
Nikko in San Francisco, CA.
Mr. Commissiong will discuss the Company's proprietary
Alzheimer's blood diagnostic LymPro Test® and the strategic plans
for Amarantus Diagnostics on Tuesday, April 7, 2015, from
10:30-11:30 a.m. Pacific Daylight Time during the Treatments for
Alzheimer's and Cognitive Disorders session focused on the
neurodegenerative disorders horizon for symptom improvement,
disease modification and the ability for earlier or more accurate
diagnosis to improve outcomes.
About the Neurotech Investing and Partnering
Conference
Now in its 10th year, the Neurotech Investing and Partnering
Conference is the premier partnering and investing conference for
the neurotechnology industry including pharmaceuticals, medical
devices, software and diagnostics for the brain and nervous system.
Organized by the Neurotechnology Industry Organization and our
partner NeuroInsights, the 10th annual conference will be held on
Tuesday and Wednesday, April 7-8, 2015 at the Hotel Nikko in San
Francisco. The Neurotech Investing and Partnering Conference is a
global forum where investors, executives, entrepreneurs, scientists
and others involved in the development of new treatments and
diagnostics for the brain and nervous system come together to shape
the future of their organization and the industry.
About LymPro Test®
The Lymphocyte Proliferation Test (LymPro Test®) is a diagnostic
blood test that determines the ability of peripheral blood
lymphocytes to withstand an exogenous mitogenic stimulation that
induces them to enter the cell cycle. It is believed that certain
diseases, most notably Alzheimer's disease, are the result of
compromised cellular machinery that leads to aberrant cell cycle
re-entry by neurons. LymPro is unique in the use of peripheral
blood lymphocytes (PBLs) as a surrogate for neuronal cell function,
suggesting a common immune-based relationship between PBLs and
neurons in the brain.
About Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings (AMBS) is a biotechnology company
developing treatments and diagnostics for diseases in the areas of
neurology, psychiatry, ophthalmology and regenerative medicine.
AMBS has licensed Eltoprazine, a Phase 2b ready small molecule
indicated for Parkinson's disease Levodopa-induced dyskinesia and
adult ADHD. AMBS has an exclusive worldwide license to the
Lymphocyte Proliferation test, (LymPro Test®), which was developed
by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, for
Alzheimer's disease and owns the intellectual property rights to a
therapeutic protein known as mesencephalic-astrocyte-derived
neurotrophic factor ("MANF") and is developing MANF-based products
as treatments for brain and ophthalmic disorders. AMBS also owns
intellectual property for the diagnosis of Parkinson's disease
(NuroPro) and the discovery of neurotrophic factors
(PhenoGuard™).
In November 2014, AMBS entered into an exclusive option
agreement with Lonza Walkersville, Inc., a subsidiary of Lonza
Group Ltd., to acquire Cutanogen Corporation, a subsidiary of Lonza
Walkersville, to develop Engineered Skin Substitute (ESS-W), an
autologous skin replacement product for the treatment of Stage 3
and Stage 4 intractable severe burns.
On January 12, 2015, AMBS announced the acquisition of DioGenix,
Inc., a specialized neuro-diagnostics company, and owns the rights
to MSPrecise®, a proprietary next-generation DNA sequencing (NGS)
assay for the identification of patients with relapsing-remitting
multiple sclerosis (RRMS) at first clinical presentation. On
January 15, 2015, AMBS executed a one-year exclusive option
agreement with Georgetown University to enter into a license for
the patent rights related to certain blood based biomarkers for
memory loss and Alzheimer's disease jointly owned by Georgetown
University and University of Rochester. For further information
please visit www.Amarantus.com, or connect with the Company on
Facebook, LinkedIn, Twitter and Google+.
Forward-Looking Statements
Certain statements, other than purely historical information,
including estimates, projections, statements relating to our
business plans, objectives, and expected operating results, and the
assumptions upon which those statements are based, are
forward-looking statements. These forward-looking statements
generally are identified by the words "believes," "project,"
"expects," "anticipates," "estimates," "intends," "strategy,"
"plan," "may," "will," "would," "will be," "will continue," "will
likely result," and similar expressions. Forward-looking statements
are based on current expectations and assumptions that are subject
to risks and uncertainties which may cause actual results to differ
materially from the forward-looking statements. Our ability to
predict results or the actual effect of future plans or strategies
is inherently uncertain. Factors which could have a material
adverse effect on our operations and future prospects on a
consolidated basis include, but are not limited to: changes in
economic conditions, legislative/regulatory changes, availability
of capital, interest rates, competition, and generally accepted
accounting principles. These risks and uncertainties should also be
considered in evaluating forward-looking statements and undue
reliance should not be placed on such statements.
CONTACT: Investor and Media Contact:
Jenene Thomas
Jenene Thomas Communications, LLC
Investor Relations and Corporate Communications Advisor
T: (US) 908.938.1475
E: jenene@jenenethomascommunications.com
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Apr 2024 to May 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From May 2023 to May 2024